Screener / SEC EDGAR /CIK 0000914156 /10-K filed Feb 27, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

UFP Technologies Inc UFPT

Compare with peers Embed
Earnings releases

Latest results release: Nov 3, 2026

8-K item 2.02, exhibit 99

What UFPT's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 3, 2026 · EX-99.1

UFP Technologies Announces Strong Q3 Results

Open on SEC

Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 million, 11.6% higher than 2025 third quarter sales of $154.6 million. Generally accepted accounting principles ("GAAP") and adjusted earnings per diluted common share outstanding ("EPS") for the quarter ended September 30, 2026 were $2.64 and $2.88, respectively. Net income for the nine- month period ended September 30, 2026 was $59.0 million, 16.2% higher than net income of $50.7 million for the same period in 2025. Net sales for the nine- month period ended September 30, 2026 were $500.6 million, compared to sales of $453.9 million in the same period of 2025. GAAP and adjusted EPS for the nine- month period ended September 30, 2026 were $7.56 and $8.28, respectively.

Throughout this news release, reference is made to non-GAAP measures including organic sales growth; adjusted selling, general and administrative expenses ("SG&A"); adjusted operating income; adjusted net income and EPS; and EBITDA and adjusted EBITDA. Please see “Non-GAAP Financial Information” at the end of this news release.

"Our third quarter and year-to-date results reflect continued solid execution across the UFP platform and progress toward our long-term growth strategy,” said Mitch Rock, President and Chief Executive Officer. “In the third quarter, sales grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%, and adjusted operating income grew 14.5%. MedTech sales grew 12.5%, reflecting broad-based demand across our portfolio.”

“Year-to-date sales increased 10.3% to $500.6 million. MedTech sales grew 11.7% and our top five MedTech customers collectively grew 11.7%, reinforcing the balance, diversity, and durability of our portfolio of operating businesses.”

“Operationally, we are seeing meaningful improvements across our businesses, including scaling new programs in the Dominican Republic and margin improvements in our legacy UFP operations. We are also seeing strong results from investments we have made to broaden our capabilities. Our 2025 investment in TPI has exceeded our expectations and provides an initial position in injection molding, a technology where we see opportunity to expand across UFP. We have also made significant year-over-year progress at AJR in both the U.S. and the Dominican Republic. However, scheduled program transfers to the Dominican Republic and margin improvement remain behind plan."

“Looking ahead to 2027, we are optimistic about the strength and positioning of UFP. We have invested in additional capacity at DAS Medical to support double- digit growth and have continued to build and invest in the team. We also continue to see attractive acquisition opportunities and are making progress on several of them."

"In parallel, we are working to expand our credit facility, increasing our capacity to invest in high-quality businesses that meet our investment criteria. With a strong balance sheet and an expanded team, we have the capacity to effectively onboard larger businesses and create long-term value.”

• Sales for the third quarter increased 11.6% to $172.4 million, from $154.6 million in the same period of 2025. Year-to-date sales through September increased 10.3% to $500.6 million, from $453.9 million in the same period of 2025. Organic sales growth for the three- and nine-month periods ended September 30, 2026, was 11.1% and 7.9%, respectively.

• Gross profit as a percentage of sales (“Gross Margin”) increased to 29.4% for the third quarter of 2026, from 27.7% in the same quarter of 2025. Gross Margin for the nine-month period ended September 30, 2026, increased to 29.2% from 28.3% in the same period of 2025.

• SG&A increased 21.4% to $23.2 million for the third quarter of 2026, from $19.1 million in the same quarter of 2025. As a percentage of sales, SG&A increased to 13.4% in the third quarter of 2026, from 12.3% in the same period of 2025. For the nine-month period ended September 30, 2026, SG&A increased 18.5% to $66.9 million from $56.5 million in the same period of 2025. As a percentage of sales, SG&A in the nine-month period ended September 30, 2026, increased to 13.4% from 12.4% in the same period of 2025. As a percentage of sales, adjusted SG&A increased to 12.0% and 11.9% for the three- and nine-month periods ended September 30, 2026, respectively, from 10.7% and 10.8%, respectively, in the same periods of 2025.

• Operating income increased 18.1% to $27.6 million for the third quarter of 2026 , from $23.4 million in the same quarter of 2025 . Adjusted operating income for the third quarter of 2026 increased 14.5% to $30.1 million from $26.3 million in the same period of 2025. For the nine-month period ended September 30, 2026, operating income increased 11.6% to $79.1 million from $70.8 million in the same period of 2025. Adjusted operating income for the nine-month period ended September 30, 2026, increased 9.0% to $86.6 million from $79.4 million in the same period of 2025.

• Net income increased 25.8% to $20.6 million in the third quarter of 2026, compared to $16.4 million in the same period of 2025. Adjusted net income increased 21.1% to $22.5 million in the third quarter of 2026, from $18.6 million in the same period of 2025. GAAP and adjusted diluted EPS for the third quarter of 2026 were $2.64 and $2.88, respectively, as compared to $2.11 and $2.39, respectively, for the same period in 2025. For the nine-month period ended September 30, 2026, net income increased 16.2% to $59.0 million, from $50.7 million in the same period of 2025. Adjusted net income increased 13.0% to $64.5 million for the nine-month period ended September 30, 2026, from $57.1 million in the same period of 2025.

• Adjusted EBITDA for the third quarter of 2026 increased 15.3% to $35.4 million from $30.7 million in the third quarter of 2025 . Adjusted EBITDA for the nine- month period ended September 30, 2026, increased 10.7% to $102.8 million, from $92.8 million in the same period of 2025.

UFP Technologies is a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products. The company’s single-use and single-patient devices and components are used across a wide range of medical products in segments including robotic assisted surgery, patient beds and handling, infection control, cardiovascular, orthopedics and spine and wound care. For more information, visit ufpt.com.

The Company has scheduled a conference call on November 4th, 2026, at 8:30 AM Eastern time. Participants may join the call using the following dial-in numbers: • Toll-Free: 1-412-206-6478

• International: 1-833-890-4010 A live webcast of the conference call and accompanying materials will be available at www.ufpt.com. A replay of the webcast will be accessible following the event on the Company’s Investor Relations website at https://ufpt.com/investors/.

Certain statements in this press release may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to known and unknown risks, uncertainties, and other factors, which may cause our or our industry’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance and may be identified by words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” or similar words. Such statements include, but are not limited to, statements about the Company’s future financial or operating performance; statements of the Company about the

marketplace and the Company’s position in the marketplace; statements about the Company’s acquisition strategies and opportunities and the Company’s growth potential and strategies for growth; statements about the integration and performance of recent acquisitions, including that such acquisitions will be accretive to the Company's revenue, income and EBITDA; statements about the Company’s ability to realize the benefits expected from our pipeline of acquisition opportunities and recently completed acquisitions, including any related synergies; expectations regarding an increase in revenue as a result of the Company’s new programs and facility expansions in the Dominican Republic and the completion of program transfers to the Dominican Republic; statements about the Company’s ability to realize the benefits expected from investments in TPI, AJR and DAS Medical and otherwise; expectations regarding an increase in product demand as a result of negotiating favorable terms with the Company’s largest customer; efforts to expand our credit facility; expectations regarding customer demand; and any indication that the Company may be able to sustain or increase its sales, gross margins, earnings or earnings per share, or its sales, gross margins, earnings or earnings per share growth rates. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the Company's general ability to execute its business plans; industry conditions, including fluctuations in supply, demand and prices for the Company's products and services due to inflation or otherwise; risks associated with governmental regulations and/or sanctions affecting the import and export of products, including tariffs, global trade barriers, additional taxes, tariff increases or uncertainties, cash repatriation restrictions, retaliations and boycotts between the U.S. and other countries; risks associated with domestic, regional and global political risks and uncertainties, including the ongoing conflict between the U.S. and Iran; risks relating to cyber security, such as cyber-attacks on the Company’s information technology infrastructure, products, suppliers, customers and partners, including the potential consequences of the Cyber Incident (as defined in Item 1C, Cybersecurity in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025) could result in data or financial loss, reputational harm, business disruption, damage to our relationships with customers, consumers, employees and third parties on which we rely, litigation, regulatory investigations, enforcement actions or other negative impacts under cybersecurity related regulations or otherwise; risks associated with our or third-party use of artificial intelligence technologies; risks related to our indebtedness and compliance with covenants contained in our financing arrangements, whether our efforts to expand our credit facility will succeed on favorable terms if at all and whether any available financing may be sufficient to address our needs; risks relating to delayed payments by our customers and the potential for reduced or canceled orders; risks related to customer concentration; risks associated with new product and program launches; risks relating to our performance and the performance of our counterparties under the agreements we have entered into; the risk that our two largest customers, on whom we depend for a substantial portion of our annual revenues, will not purchase the expected volume of goods under the supply agreements we have entered into with them because, among other things, they no longer require the products at all or to the degree they anticipated or because, among other things, our largest customer decides to manufacture the products itself or through one of its affiliates or it obtains the products from other listed suppliers specified in our agreement; risks associated with our inability to extend or otherwise renegotiate favorable terms with the Company's largest customer, if at all; the risk that we will not achieve expected rebates under the applicable supply agreement; risks relating to our ability to maintain increased levels of production at profitable levels, if at all; or to continue to increase production rates and/or timely and successfully transfer programs to the Dominican Republic and risks relating to disruptions and delays in our supply chain or labor force; risks relating to our new programs and facility expansions in the Dominican Republic; risks associated with the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions, the integration of any such acquisition candidates, the value of those acquisitions to our customers and shareholders, and the financing of such acquisitions; risks related to inflation and other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's filings with the Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. The Company expressly disclaims

any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which any such statement is based. Forward-looking statements are also subject to the risks and other issues described below under “Non-GAAP Financial Information,” which could cause actual results to differ materially from current expectations included in the Company’s forward-looking statements included in this press release.

This news release includes non-GAAP performance measures. Management considers organic sales growth, adjusted SG&A, adjusted operating income, adjusted net income and EPS, EBITDA and adjusted EBITDA, non-GAAP measures. The Company uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company’s historical operating results. The Company’s management believes these non-GAAP measures are useful in evaluating the Company’s operating performance and are similar to measures reported by publicly listed U.S. competitors, and regularly used by securities analysts, institutional investors, and other interested parties in analyzing operating performance and prospects. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. By providing these non-GAAP measures, the Company’s management intends to provide investors with a meaningful, consistent comparison of the Company’s performance for the periods presented. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures of performance used by other companies in other industries or within the same industry.

Full text with the tables
                                                                                
                  UFP Technologies Announces Strong Q3 Results                  
                                                                                
Newburyport, Mass., November 3, 2026. UFP Technologies, Inc. (Nasdaq: UFPT), a
trusted contract development and manufacturing organization specializing in
comprehensive solutions for medical devices, sterile packaging and other highly
engineered custom products, today reported net income of $20.6 million for its
third quarter ended September 30, 2026, 25.8% higher than net income of $16.4
million for the third quarter of 2025. Net sales for the quarter ended September
30, 2026 were $172.4 million, 11.6% higher than 2025 third quarter sales of
$154.6 million. Generally accepted accounting principles ("GAAP") and adjusted
earnings per diluted common share outstanding ("EPS") for the quarter ended
September 30, 2026 were $2.64 and $2.88, respectively. Net income for the nine-
month period ended September 30, 2026 was $59.0 million, 16.2% higher than net
income of $50.7 million for the same period in 2025. Net sales for the nine-
month period ended September 30, 2026 were $500.6 million, compared to sales of
$453.9 million in the same period of 2025. GAAP and adjusted EPS for the nine-
month period ended September 30, 2026 were $7.56 and $8.28, respectively.

Throughout this news release, reference is made to non-GAAP measures including
organic sales growth; adjusted selling, general and administrative expenses
("SG&A"); adjusted operating income; adjusted net income and EPS; and EBITDA and
adjusted EBITDA. Please see “Non-GAAP Financial Information” at the end of this
news release.

"Our third quarter and year-to-date results reflect continued solid execution
across the UFP platform and progress toward our long-term growth strategy,” said
Mitch Rock, President and Chief Executive Officer. “In the third quarter, sales
grew 11.6%, including 11.1% organic growth, gross margins increased to 29.4%,
and adjusted operating income grew 14.5%. MedTech sales grew 12.5%, reflecting
broad-based demand across our portfolio.”

“Year-to-date sales increased 10.3% to $500.6 million. MedTech sales grew 11.7%
and our top five MedTech customers collectively grew 11.7%, reinforcing the
balance, diversity, and durability of our portfolio of operating businesses.”

“Operationally, we are seeing meaningful improvements across our businesses,
including scaling new programs in the Dominican Republic and margin improvements
in our legacy UFP operations. We are also seeing strong results from investments
we have made to broaden our capabilities. Our 2025 investment in TPI has
exceeded our expectations and provides an initial position in injection molding,
a technology where we see opportunity to expand across UFP. We have also made
significant year-over-year progress at AJR in both the U.S. and the Dominican
Republic. However, scheduled program transfers to the Dominican Republic and
margin improvement remain behind plan."

“Looking ahead to 2027, we are optimistic about the strength and positioning of
UFP. We have invested in additional capacity at DAS Medical to support double-
digit growth and have continued to build and invest in the team. We also
continue to see attractive acquisition opportunities and are making progress on
several of them."

"In parallel, we are working to expand our credit facility, increasing our
capacity to invest in high-quality businesses that meet our investment criteria.
With a strong balance sheet and an expanded team, we have the capacity to
effectively onboard larger businesses and create long-term value.”

Financial Highlights:

• Sales for the third quarter increased 11.6% to $172.4 million, from $154.6
million in the same period of 2025. Year-to-date sales through September
increased 10.3% to $500.6 million, from $453.9 million in the same period of
2025. Organic sales growth for the three- and nine-month periods ended September
30, 2026, was 11.1% and 7.9%, respectively.

• Gross profit as a percentage of sales (“Gross Margin”) increased to 29.4% for
the third quarter of 2026, from 27.7% in the same quarter of 2025. Gross Margin
for the nine-month period ended September 30, 2026, increased to 29.2% from
28.3% in the same period of 2025.

• SG&A increased 21.4% to $23.2 million for the third quarter of 2026, from
$19.1 million in the same quarter of 2025. As a percentage of sales, SG&A
increased to 13.4% in the third quarter of 2026, from 12.3% in the same period
of 2025. For the nine-month period ended September 30, 2026, SG&A increased
18.5% to $66.9 million from $56.5 million in the same period of 2025. As a
percentage of sales, SG&A in the nine-month period ended September 30, 2026,
increased to 13.4% from 12.4% in the same period of 2025. As a percentage of
sales, adjusted SG&A increased to 12.0% and 11.9% for the three- and nine-month
periods ended September 30, 2026, respectively, from 10.7% and 10.8%,
respectively, in the same periods of 2025.

• Operating income increased 18.1% to $27.6 million for the third quarter of
2026 , from $23.4 million in the same quarter of 2025 . Adjusted operating
income for the third quarter of 2026 increased 14.5% to $30.1 million from $26.3
million in the same period of 2025. For the nine-month period ended September
30, 2026, operating income increased 11.6% to $79.1 million from $70.8 million
in the same period of 2025. Adjusted operating income for the nine-month period
ended September 30, 2026, increased 9.0% to $86.6 million from $79.4 million in
the same period of 2025.

• Net income increased 25.8% to $20.6 million in the third quarter of 2026,
compared to $16.4 million in the same period of 2025. Adjusted net income
increased 21.1% to $22.5 million in the third quarter of 2026, from $18.6
million in the same period of 2025. GAAP and adjusted diluted EPS for the third
quarter of 2026 were $2.64 and $2.88, respectively, as compared to $2.11 and
$2.39, respectively, for the same period in 2025. For the nine-month period
ended September 30, 2026, net income increased 16.2% to $59.0 million, from
$50.7 million in the same period of 2025. Adjusted net income increased 13.0% to
$64.5 million for the nine-month period ended September 30, 2026, from $57.1
million in the same period of 2025.

• Adjusted EBITDA for the third quarter of 2026 increased 15.3% to $35.4 million
from $30.7 million in the third quarter of 2025 . Adjusted EBITDA for the nine-
month period ended September 30, 2026, increased 10.7% to $102.8 million, from
$92.8 million in the same period of 2025.
                                                                                
  About UFP Technologies, Inc.                                                  
                                                                                
UFP Technologies is a trusted contract development and manufacturing
organization specializing in comprehensive solutions for medical devices,
sterile packaging and other highly engineered custom products. The company’s
single-use and single-patient devices and components are used across a wide
range of medical products in segments including robotic assisted surgery,
patient beds and handling, infection control, cardiovascular, orthopedics and
spine and wound care. For more information, visit ufpt.com.

Contact: Ron Lataille

978-234-0926
                                                                                
                  Consolidated Condensed Statements of Income                   
                                                                                
                     (in thousands, except per share data)                      
                                                                                
                                  (Unaudited)                                   
                                                                                
           Three                               Nine                             
           Months                              Months                           
           Ended    Septe…                     Ended   Septem…                  
           2026        30,    2025             2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $        172,4…    $     154,558    $       500,600    $     453,8…  
  sales                                                                         
  Cost                                                                          
  of                121,6…          111,811            354,557          325,4…  
  sales                                                                         
  Gross             50,763           42,747            146,043          128,4…  
  prof…                                                                         
  Sell…                                                                         
  gene…                                                                         
  &                 23,154           19,069             66,928          56,474  
  admi…                                                                         
  expe…                                                                         
  Acqu…                 12               14                 84             334  
  costs                                                                         
  Chan…                                                                         
  in                                                                            
  fair                                                                          
  value                  —              263                  —             789  
  of                                                                            
  cont…                                                                         
  cons…                                                                         
  (Gai…                                                                         
  loss                                                                          
  on                                                                            
  disp…                                                                         
  of                    -9               22                -41              11  
  prop…                                                                         
  plant                                                                         
  &                                                                             
  equi…                                                                         
  Oper…             27,606           23,379             79,072          70,834  
  inco…                                                                         
  Inte…                                                                         
  expe…              1,492            2,393              4,940           7,873  
  net                                                                           
  Other                 -6              -78                -24             -10  
  inco…                                                                         
  Inco…                                                                         
  befo…                                                                         
  inco…             26,120           21,064             74,156          62,971  
  tax                                                                           
  expe…                                                                         
  Inco…                                                                         
  tax                5,503            4,681             15,193          12,224  
  expe…                                                                         
  Net      $        20,617    $      16,383    $        58,963    $     50,747  
  inco…                                                                         
  Net                                                                           
  inco…    $          2.66    $        2.12    $          7.62    $       6.59  
  per                                                                           
  share                                                                         
  Net                                                                           
  inco…                                                                         
  per      $          2.64    $        2.11    $          7.56    $       6.52  
  dilu…                                                                         
  share                                                                         
  Weig…                                                                         
  aver…                                                                         
  comm…              7,746            7,712              7,736           7,703  
  shar…                                                                         
  outs…                                                                         
  Weig…                                                                         
  aver…                                                                         
  dilu…              7,806            7,780              7,795           7,783  
  comm…                                                                         
  shar…                                                                         
  outs…                                                                         
                                                                                
                                                                                
                     Consolidated Condensed Balance Sheets                      
                                                                                
                                 (in thousands)                                 
                                                                                
                                  (Unaudited)                                   
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets:                                                                       
  Cash and cash equivalents      $              20,625    $             20,301  
  Receivables, net                              97,154                  82,914  
  Inventories                                   98,148                  86,856  
  Other current assets                          14,711                  10,930  
  Property, plant, and                          78,582                  79,109  
  equipment, net                                                                
  Goodwill                                     198,875                 197,403  
  Intangible assets, net                       136,194                 140,849  
  Other assets                                  38,346                  36,715  
  Total assets                   $             682,635    $            655,077  
  Liabilities and equity:                                                       
  Accounts payable               $              26,488    $             24,289  
  Current portion of                            12,500                  12,500  
  long-term debt                                                                
  Other current liabilities                     38,371                  38,073  
  Long-term debt, excluding                                                     
  current                                       83,500                 122,955  
  installments                                                                  
  Other liabilities                             36,061                  33,383  
  Total liabilities                            196,920                 231,200  
  Total equity                                 485,715                 423,877  
  Total liabilities and                                                         
  stockholders'                  $             682,635    $            655,077  
  equity                                                                        
                                                                                
                                                                                
  Conference Call                                                               
                                                                                
The Company has scheduled a conference call on November 4th, 2026, at 8:30 AM
Eastern time. Participants may join the call using the following dial-in
numbers:
• Toll-Free: 1-412-206-6478

• International: 1-833-890-4010
A live webcast of the conference call and accompanying materials will be
available at www.ufpt.com.
A replay of the webcast will be accessible following the event on the Company’s
Investor Relations website at https://ufpt.com/investors/.
                                                                                
  Forward-Looking Statements                                                    
                                                                                
Certain statements in this press release may be considered “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are subject to known and unknown risks, uncertainties, and
other factors, which may cause our or our industry’s actual results,
performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements generally relate to future events or the
Company’s future financial or operating performance and may be identified by
words such as “may,” “should,” “expect,” “intend,” “will,” “estimate,”
“anticipate,” “believe,” “predict,” or similar words. Such statements include,
but are not limited to, statements about the Company’s future financial or
operating performance; statements of the Company about the

marketplace and the Company’s position in the marketplace; statements about the
Company’s acquisition strategies and opportunities and the Company’s growth
potential and strategies for growth; statements about the integration and
performance of recent acquisitions, including that such acquisitions will be
accretive to the Company's revenue, income and EBITDA; statements about the
Company’s ability to realize the benefits expected from our pipeline of
acquisition opportunities and recently completed acquisitions, including any
related synergies; expectations regarding an increase in revenue as a result of
the Company’s new programs and facility expansions in the Dominican Republic and
the completion of program transfers to the Dominican Republic; statements about
the Company’s ability to realize the benefits expected from investments in TPI,
AJR and DAS Medical and otherwise; expectations regarding an increase in product
demand as a result of negotiating favorable terms with the Company’s largest
customer; efforts to expand our credit facility; expectations regarding customer
demand; and any indication that the Company may be able to sustain or increase
its sales, gross margins, earnings or earnings per share, or its sales, gross
margins, earnings or earnings per share growth rates. Factors that may cause
actual results to differ materially from current expectations include, but are
not limited to: the Company's general ability to execute its business plans;
industry conditions, including fluctuations in supply, demand and prices for the
Company's products and services due to inflation or otherwise; risks associated
with governmental regulations and/or sanctions affecting the import and export
of products, including tariffs, global trade barriers, additional taxes, tariff
increases or uncertainties, cash repatriation restrictions, retaliations and
boycotts between the U.S. and other countries; risks associated with domestic,
regional and global political risks and uncertainties, including the ongoing
conflict between the U.S. and Iran; risks relating to cyber security, such as
cyber-attacks on the Company’s information technology infrastructure, products,
suppliers, customers and partners, including the potential consequences of the
Cyber Incident (as defined in Item 1C, Cybersecurity in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2025) could result in data or
financial loss, reputational harm, business disruption, damage to our
relationships with customers, consumers, employees and third parties on which we
rely, litigation, regulatory investigations, enforcement actions or other
negative impacts under cybersecurity related regulations or otherwise; risks
associated with our or third-party use of artificial intelligence technologies;
risks related to our indebtedness and compliance with covenants contained in our
financing arrangements, whether our efforts to expand our credit facility will
succeed on favorable terms if at all and whether any available financing may be
sufficient to address our needs; risks relating to delayed payments by our
customers and the potential for reduced or canceled orders; risks related to
customer concentration; risks associated with new product and program launches;
risks relating to our performance and the performance of our counterparties
under the agreements we have entered into; the risk that our two largest
customers, on whom we depend for a substantial portion of our annual revenues,
will not purchase the expected volume of goods under the supply agreements we
have entered into with them because, among other things, they no longer require
the products at all or to the degree they anticipated or because, among other
things, our largest customer decides to manufacture the products itself or
through one of its affiliates or it obtains the products from other listed
suppliers specified in our agreement; risks associated with our inability to
extend or otherwise renegotiate favorable terms with the Company's largest
customer, if at all; the risk that we will not achieve expected rebates under
the applicable supply agreement; risks relating to our ability to maintain
increased levels of production at profitable levels, if at all; or to continue
to increase production rates and/or timely and successfully transfer programs to
the Dominican Republic and risks relating to disruptions and delays in our
supply chain or labor force; risks relating to our new programs and facility
expansions in the Dominican Republic; risks associated with the identification
of suitable acquisition candidates and the successful, efficient execution of
acquisition transactions, the integration of any such acquisition candidates,
the value of those acquisitions to our customers and shareholders, and the
financing of such acquisitions; risks related to inflation and other risks and
uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary
Note Regarding Forward-Looking Statements" in the Company's filings with the
Securities and Exchange Commission ("SEC"), which are available on the SEC's
website at www.sec.gov. The Company expressly disclaims

any obligation or undertaking to release publicly any updates or revisions to
any such statement to reflect any change in the Company’s expectations or any
change in events, conditions, or circumstances on which any such statement is
based. Forward-looking statements are also subject to the risks and other issues
described below under “Non-GAAP Financial Information,” which could cause actual
results to differ materially from current expectations included in the Company’s
forward-looking statements included in this press release.
                                                                                
   Non-GAAP Financial Information                                               
                                                                                
This news release includes non-GAAP performance measures. Management considers
organic sales growth, adjusted SG&A, adjusted operating income, adjusted net
income and EPS, EBITDA and adjusted EBITDA, non-GAAP measures. The Company uses
these non-GAAP financial measures to facilitate management's financial and
operational decision-making, including evaluation of the Company’s historical
operating results. The Company’s management believes these non-GAAP measures are
useful in evaluating the Company’s operating performance and are similar to
measures reported by publicly listed U.S. competitors, and regularly used by
securities analysts, institutional investors, and other interested parties in
analyzing operating performance and prospects. These non-GAAP financial measures
reflect an additional way of viewing aspects of the Company's operations that,
when viewed with GAAP results and the reconciliations to corresponding GAAP
financial measures, may provide a more complete understanding of factors and
trends affecting the Company’s business. By providing these non-GAAP measures,
the Company’s management intends to provide investors with a meaningful,
consistent comparison of the Company’s performance for the periods presented.
These non-GAAP financial measures should be considered supplemental to, and not
a substitute for, financial information prepared in accordance with GAAP. The
Company's definition of these non-GAAP measures may differ from similarly titled
measures of performance used by other companies in other industries or within
the same industry.
                                                                                
                    Organic Sales Growth Rate Reconciliation                    
                                                                                
                                 (in thousands)                                 
                                                                                
         Thr…                               Nine                                
         Mon…                               Mont…                               
         End…                               Ended                               
         Sep…                               Sept…                               
         30,                                30,                                 
         2026              2025             2026                  2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Ov…                                                                           
  net    $     172,…       $     154…       $      500…                   $45…  
  sa…                                                                           
  Net                                                                           
  sa…                                                                           
  fr…           -725                   —                 -10,…               —  
  ac…                                                                           
  op…                                                                           
  Or…    $     171,…       $     154…                    $489…            $45…  
  sa…                                                                           
  Or…                                                                           
  gr…           11.1  %                             7.9      %                  
  sa…                                                                           
  ra…                                                                           
                                                                                
          Adjusted Selling, General and Administrative Expenses (SG&A)          
                                                                                
                                 (in thousands)                                 
                                                                                
          Three                               Nine                              
          Mont…                               Mont…                             
          Ended  Sept…                        Ended  Sep…                       
          2026     30,       2025             2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  SG&A    $      23,1…       $     19,…       $      66,…       $     56,4…     
  (GA…                                                                          
  Amo…                                                                          
  of             -2,5…             -2,…              -7,…             -7,2…     
  int…                                                                          
  ass…                                                                          
  Adj…                                                                          
  SG&A    $      20,6…       $     16,…       $      59,…       $     49,1…     
  (No…                                                                          
  Adj…                                                                          
  SG&A                                                                          
  as a            12.0  %          10.7  %           11.9  %           10.8  %  
  % of                                                                          
  sal…                                                                          
                                                                                
                                                                                
                    Adjusted Operating Income Reconciliation                    
                                                                                
                                 (in thousands)                                 
                                                                                
            Three                              Nine                             
            Months                             Months                           
            Ended    Septe…                    Ended    Septe…                  
            2026        30,    2025            2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Opera…                                                                        
  income    $        27,606    $     23,379    $        79,072    $     70,834  
  (GAAP)                                                                        
  Adjus…                                                                        
  Purch…                                                                        
  accou…                  —             146                  —             146  
  expen…                                                                        
  Acqui…                 12              14                 84             334  
  costs                                                                         
  Change                                                                        
  in                                                                            
  fair                                                                          
  value                   —             263                  —             789  
  of                                                                            
  conti…                                                                        
  consi…                                                                        
  Amort…                                                                        
  of                  2,500           2,481              7,458           7,279  
  intan…                                                                        
  assets                                                                        
  (Gain)                                                                        
  loss                                                                          
  on                                                                            
  dispo…                 -9              22                -41              11  
  of                                                                            
  fixed                                                                         
  assets                                                                        
  Adjus…                                                                        
  opera…    $        30,109    $     26,305    $        86,573    $     79,393  
  income                                                                        
  (Non-…                                                                        
                                                                                
    Adjusted Net Income per Diluted Common Share Outstanding Reconciliation     
                                                                                
                     (in thousands, except per share data)                      
                                                                                
          Three                                   Nine                          
          Months                                  Mont…                         
          Ended   Sept…                           Ended  Septe…                 
          2026      30,           2025            2026      30,    2025         
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inc…    $       20,6…           $     16,383    $      58,963    $     50,7…  
  (GA…                                                                          
  Adj…                                                                          
  (net                                                                          
  of                                                                            
  tax…                                                                          
  Pur…                                                                          
  acc…                —                    146                —            146  
  exp…                                                                          
  Acq…                      12              14               84            334  
  cos…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…                       —             263                —            789  
  of                                                                            
  con…                                                                          
  con…                                                                          
  Amo…                                                                          
  of                     2,500           2,481            7,458          7,279  
  int…                                                                          
  ass…                                                                          
  (Ga…                                                                          
  loss                                                                          
  on                                                                            
  dis…                      -9              22              -41             11  
  of                                                                            
  fix…                                                                          
  ass…                                                                          
  Tax…                                                                          
  on               -645                   -753           -1,932          -2,2…  
  adj…                                                                          
  Adj…                                                                          
  net     $       22,4…           $     18,556    $      64,532    $     57,1…  
  inc…                                                                          
  (No…                                                                          
  Adj…                                                                          
  net                                                                           
  inc…                                                                          
  per     $        2.88           $       2.39    $        8.28    $      7.34  
  dil…                                                                          
  sha…                                                                          
  out…                                                                          
  (No…                                                                          
  Wei…                                                                          
  ave…                                                                          
  dil…            7,806                  7,780            7,795          7,783  
  com…                                                                          
  sha…                                                                          
  out…                                                                          
                                                                                
                                                                                
                             EBITDA Reconciliation                              
                                                                                
                                 (in thousands)                                 
                                                                                
           Three                             Nine                               
           Months                            Mont…                              
           Ended   Septe…                    Ended  Septe…                      
           2026       30,    2025            2026      30,    2025              
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inco…    $       20,617    $     16,383    $      58,963    $     50,7…       
  (GAA…                                                                         
  Inco…                                                                         
  tax               5,503           4,681           15,193          12,2…       
  expe…                                                                         
  Inte…                                                                         
  expe…             1,492           2,393            4,940          7,873       
  net                                                                           
  Depr…             2,524           2,393            7,430          6,948       
  Amor…                                                                         
  of                2,500           2,481            7,458          7,279       
  inta…                                                                         
  asse…                                                                         
  EBIT…    $       32,636    $     28,331    $      93,984    $     85,0…       
  (Non…                                                                         
  Adju…                                                                         
  Share                                                                         
  based             2,790           1,959            8,747          6,456       
  comp…                                                                         
  Purc…                                                                         
  acco…                 —             146                —                 146  
  expe…                                                                         
  Acqu…                12              14               84            334       
  costs                                                                         
  Chan…                                                                         
  in                                                                            
  fair                                                                          
  value                 —             263                —            789       
  of                                                                            
  cont…                                                                         
  cons…                                                                         
  (Gai…                                                                         
  loss                                                                          
  on                                                                            
  disp…                -9              22              -41             11       
  of                                                                            
  fixed                                                                         
  asse…                                                                         
  Adju…                                                                         
  EBIT…    $       35,429    $     30,735    $      102,7…    $     92,8…       
  (Non…                                                                         
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/UFPT/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.